Advertisement SIRS-Lab names new executive vice-president of corporate development - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

SIRS-Lab names new executive vice-president of corporate development

SIRS-Lab, a developer of molecular diagnostics, has appointed Edward Currie as its new executive vice-president of corporate development.

In this newly created role, Dr Currie will drive partnering, licensing, companion diagnostics, and corporate business development activities at Sirs-Lab.

Dr Currie, a physician specialized in clinical microbiology and infectious disease, brings 20 years of diagnostic and pharmaceutical industry experience at Eli Lilly, F Hoffmann-La Roche, IBM, and, most recently, as COO of Kuros BioSurgery.

Stefan Russwurm, CEO of SIRS-Lab, said: “We are delighted to welcome Dr Currie here at Sirs-Lab. His highly regarded wealth of experience and an impressive track-record in the medical and diagnostic area, especially in the field of personalized medicine, will benefit us greatly in expanding our strategic partnerships.”